Litigation Details for Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd. (D. Del. 2020)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd. (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-10-23 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 10,124,000; 7,314,938; 7,745,460; 7,790,743; 7,928,122; 8,084,047; 8,168,655; 8,367,701; 8,592,450; 8,927,574; 9,085,553; 9,216,174; 9,353,088; 9,447,077; 9,890,141 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-10-26 | 1 | Complaint | ,174 (“the ’174 patent”); U.S. Patent No. 10,124,000 (“the ’000 patent”); U.S. Patent No. 8,084,047 (…of U.S. Patent No. 7,314,938 (“the ’938 patent”); U.S. Patent No. 7,745,460 (“the ’460 patent”); U.S.…U.S. Patent No. 7,790,743 (“the ’743 patent”); U.S. Patent No. 7,928,122 (“the ’122 patent”); U.S. Patent… (“the ’047 patent”); U.S. Patent No. 8,592,450 (“the ’450 patent”); U.S. Patent No. …8,168,655 (“the ’655 patent”); U.S. Patent No. 8,367,701 (“the ’701 patent”); U.S. Patent No. 9,447,077 ( | External link to document |
| 2020-10-26 | 3 | ANDA Form | November 5, 2024 10,124,000 November 5,… Date of Expiration of Patents: U.S. Patent No. …. SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
